M&A activity snapshot
Behavioral health deal volume slowed in 2026 after a strong 2025. Mertz Taggart counted 27 closed transactions in Q2 2026, 21 traditional M&A deals and 6 growth deals. Traditional volume declined from 34 closed deals in Q1 2026 and 29 in Q2 2025, the lightest quarter in its data set going back to 2022.
Mental health is the center of the market. It led all sub-sectors with 14 closed deals, followed by autism and I/DD with 6 and addiction treatment with 2. Mental health activity is split between technology-enabled platforms and a steady base of outpatient psychiatry and community provider combinations.
Substance-use treatment is the weak spot. Addiction treatment produced only 2 of the quarter's closed deals, against 14 in mental health. Medicaid is a heavy payer for this segment, which ties its deal flow closely to Medicaid policy.
Who is buying
Hospital operators and large platforms are buying scale in outpatient and virtual care. Universal Health Services' $835 million acquisition of Talkspace was approved by shareholders May 30, 2026. Spring Health closed its acquisition of Alma, a mental health provider marketplace, which expanded its in-network provider supply. PsychPlus acquired Koa Health, a multinational digital mental health company.
Sponsor-backed platforms keep adding practices in smaller bites. In Q2 2026, Thurston Group-backed Arc Health acquired North Carolina Mental Health & Psychiatry Group. Mertz Taggart also noted that two new private equity platforms formed in the quarter.
Nonprofits and payers are active too. Nonprofit and health-system combinations accounted for roughly a third of closed traditional volume in Q2 2026, several driven by Medicaid economics. On the payer side, WPS Health Insurance acquired Mavida Health, a women's mental health platform.
What buyers look for
Payer mix comes first. Medicaid is the single largest payer of behavioral health services in the country, and buyers now discount heavy Medicaid exposure. Mertz Taggart's Kevin Taggart says buyers are underwriting Medicaid more cautiously than in years past. Commercial in-network contracts with documented rates are the most valued asset.
Service mix is the second test. VERTESS sees sustained demand for outpatient mental health, psychiatry, PHP/IOP, and evolving value-based care models.
Clinical leadership and reporting are the third. VERTESS describes the most sought-after targets as having experienced clinical leadership, diversified payor mix, scalable infrastructure, and clear, defensible performance metrics. In practice that means clinician retention, visits per clinician, no-show rates, and days in accounts receivable by payer.
Regulatory exposure gets its own workstream. DEA and HHS extended telemedicine prescribing flexibilities through December 31, 2026, but permanent rules are not final. A practice that relies on remote prescribing of controlled substances must show how its model works if the flexibilities end.
What makes a strong company
An outpatient behavioral health practice that commands a premium typically shows:
- In-network commercial contracts with several payers, and Medicaid as a minority of revenue.
- A clinician bench, including psychiatric prescribers, that does not depend on the founder's caseload.
- Measurable access and outcomes data, such as time to first appointment and standardized symptom scores.
- A telehealth and prescribing model that complies with current DEA rules and can adapt if they change.
- Clean credentialing, documentation, and billing audit results.
- Room to add higher-acuity or interventional services, such as IOP or TMS, without new licensure barriers.
Mertz Taggart summarizes the pricing gap simply: buyers are paying up for clean, in-network, growing businesses and being more diligent on everything else.
Valuation and deal structure
Behavioral-health-specific multiples for small practices are not published by the major lower-middle-market data providers. The closest proxy is GF Data's 7.7x for healthcare services in its 2026 mid-year read, which it cautioned rests on a small sample. That figure covers all healthcare services, not behavioral health alone.
Large deals show how structure bridges risk. In the announced Advantage Behavioral Health deal, founders and management are expected to receive roughly $415 million at closing, with up to $100 million more tied to milestones. Milestone payments and seller rollover are common tools for bridging valuation gaps, but no source above reports how often smaller practices use them.
State review laws affect timing. A Mertz Taggart tally finds at least 14 states now require advance notice to the attorney general or a related agency before a private equity, hedge fund, or MSO-affiliated healthcare transaction closes. Behavioral health practices that use an MSO structure should expect this review in those states.
Parity policy is unsettled. On March 30, 2026, the federal departments said they will no longer defend the mental health parity regulations they issued in September 2024. They set a target date of December 31, 2026, for the issuance of proposed regulations. Buyers should not assume the 2024 rule's network-adequacy pressure on commercial payers will hold.
Outlook
Expect outpatient mental health to keep leading volume over the next 12 to 24 months, with substance-use deals recovering slowly. Medicaid-heavy substance-use providers carry the most policy risk, since buyers are already underwriting Medicaid more cautiously than in years past.
Three dates will shape pricing: the end of DEA telemedicine flexibilities on December 31, 2026, the proposed parity rule due by the same date, and pending Medicaid policy changes. Practices with commercial in-network revenue and compliant prescribing models are best placed to hold value through those changes.
Own a behavioral health or counseling practice and want a starting point before you talk to buyers? Run the valuation tool or read the Healthcare Services M&A overview. See also: how buy-side mandates turn into PE pipelines.